Search

Your search keyword '"Eli, L.D."' showing total 9 results
Start Over Author "Eli, L.D."
9 results on '"Eli, L.D."'

1. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Author

Jhaveri, K., Eli, L.D., Wildiers, H., Hurvitz, S.A., Guerrero-Zotano, A., Unni, N., Brufsky, A., Park, H., Waisman, J., Yang, E.S., Spanggaard, I., Reid, S., Burkard, M.E., Vinayak, S., Prat, A., Arnedos, M., Bidard, F.-C., Loi, S., Crown, J., Bhave, M., Piha-Paul, S.A., Suga, J.M., Chia, S., Saura, C., Garcia-Saenz, J.Á., Gambardella, V., de Miguel, M.J., Gal-Yam, E.N., Raphael, A., Stemmer, S.M., Ma, C., Hanker, A.B., Ye, D., Goldman, J.W., Bose, R., Peterson, L., Bell, J.S.K., Frazier, A., DiPrimeo, D., Wong, A., Arteaga, C.L., and Solit, D.B.

Published
2023
Full Text
View/download PDF

2. Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: findings from the SUMMIT basket trial

Author

Goldman, J., primary, Martínez Bueno, A., additional, Dooms, C., additional, Jhaveri, K., additional, de Miguel, M.J., additional, Piha-Paul, S.A., additional, Unni, N., additional, Mahipal, A., additional, Suga, J.M., additional, Naltet, C., additional, Zick, A., additional, Antoñanzas Basa, M., additional, Crown, J., additional, Chae, Y.K., additional, DiPrimeo, D., additional, Eli, L.D., additional, McCulloch, L., additional, and Mahalingam, D., additional

Published
2022
Full Text
View/download PDF

4. 559P Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial

Author

Friedman, C.F., primary, D'Souza, A.A., additional, Tinker, A.V., additional, Corral, E., additional, Gambardella, V., additional, Goldman, J.W., additional, Loi, S., additional, Melisko, M., additional, Oaknin, A., additional, Spanggaard, I., additional, VanderWalde, A.M., additional, Frazier, A.L., additional, Zhang, B., additional, Eli, L.D., additional, and Solit, D.B., additional

Published
2022
Full Text
View/download PDF

5. 1O Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial

Author

Saura, C., primary, Vivancos, A., additional, Matito, J., additional, Wildiers, H., additional, Brufsky, A.M., additional, Oliveira, M., additional, Waters, S., additional, Hurvitz, S.A., additional, Moy, B., additional, Kim, S-B., additional, Gradishar, W.J., additional, Queiroz, G.S., additional, Cronemberger, E., additional, Bebchuk, J., additional, Keyvanjah, K., additional, Lalani, A.S., additional, Eli, L.D., additional, and Delaloge, S., additional

Published
2020
Full Text
View/download PDF

7. PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early- stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial

Author

Chia, S.K.L., Martin, M., Holmes, F.A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Mansi, J., Barrios, C.H., Gnant, M., Tomašević, Z., Denduluri, N., Šeparović, Robert, Kim, Jakobsen, E.H., Harvey, V., Robert, N., Smith, J.I.I., Harker, G., Lalani, A.S., Zhang, B., Eli, L.D., Chan, A., and Van Dang, Chi

Subjects
neratinib, trastuzumab, ExteNET studija, rani HER2 pozitivni karcinom dojke, skin and connective tissue diseases, neoplasms
Abstract

One year of neratinib treatment after trastuzumab- based adjuvant therapy significantly improves iDFS after 5 years in patients with early-stage HER2+ breast cancer. From this modest-sized exploratory cohort, it appears that PIK3CA may be a biomarker for differential sensitivity to neratinib after 1 year of trastuzumab in the adjuvant setting.These exploratory results should be validated in a larger subset.

Published
2018

8. Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT ‘basket’ trial

Author

D’Souza, A., primary, Roman, L.D., additional, Saura, C., additional, Braña, I., additional, Shapiro, G.I., additional, Passalacqua, R., additional, Piha-Paul, S., additional, Cutler, R.E., additional, Shahin, S., additional, Eli, L.D., additional, Xu, F., additional, Dujka, M., additional, Lalani, A.S., additional, Bryce, R., additional, Meric-Bernstam, F., additional, Solit, D.B., additional, and Hyman, D.M., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results